Biologics are any medicinal products containing biotechnology-derived proteins as active substance [1]. It is anticipated that within the next 5–10 years, 50% of all the drugs in development will be biological in origin. This increase in research and development of such molecules are due to their efficacy in disrupting the exact pathophysiology of the disease. Since the last decade, biologics have become the mainstay of treatment of many retinal vascular pathologies. They have transformed the visual outcomes of such diseases and have reduced the disease-related blindness. Currently, the anti-VEGF molecules being administered intravitreally are bevacizumab, ranibizumab, aflibercept and brolucizumab. Bevacizumab is being used off label in monthly dosing regimen, ranibizumab is the first FDA-approved anti-VEGF molecule for ophthalmic use in monthly dosing regimen, while aflibercept is approved by FDA for q8w dosing. Hinderances in instituting and maintaining biological therapy in ophthalmology are frequent visit to hospitals, repeated injections and the cost of the drug itself. The financial burden is found to be the major cause of patient non-compliance to monthly dosing regimen. In order to increase the dosing interval and thus reducing the cumulative cost of treatment, various regimens have been tried, most successful being Pro Re Nata and treat and extend approaches. These treatment protocols have though been shown to be inefficient in maintaining the visual gains in long term follow-up when compared with monthly dosing regimen [2]. Recently, there has been advancement in development of newer anti-VEGF agents which inherently increase the dosing interval from 4 weeks to 8–12 weeks, and thus can reduce cost. But none of the methods to reduce the financial burden is as realistic as biosimilars [3,4,5].

Biosimilars are the near-identical copies of the innovator biologic or reference product which do not have a significant difference in terms of efficacy or safety in clinical use [6]. These biosimilars have potential to reduce cost of treatment up to 30% without compromising on the dosing interval and are validated to be used in all the indications for which the reference product is approved for administration. The regulatory authorities have issued comprehensive guidelines for the development and approval of biosimilars across the globe to maintain the safety index of the molecule. These guidelines mandate the biosimilars to be proven similar to the reference product in large number of analytical studies about the structure and few clinical trials to assess the safety among the human subjects [7]. The reduced number of clinical trials, lesser investment into the research and development of molecule due to the presence of a reference product are few factors which help to reduce the cost of the drug. The presence of lower-cost options is also anticipated to increase the market competition, which also will lead to reduction in cost of therapy.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD